• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2023, Vol. 40 ›› Issue (2): 163-166.

• 药物研究 • 上一篇    下一篇

司美格鲁肽用于超重人群慢性体重管理的研究进展

霍艳超, 贾琼, 王真真, 盖克克*   

  1. 滨州医学院附属医院药学部, 山东 滨州 256603
  • 收稿日期:2023-01-03 修回日期:2023-03-21 出版日期:2023-04-28 发布日期:2023-04-28

Research Progress of Smeiglutide for Chronic Weight Management in Overweight Population#br#     

  1. Department of pharmacy, Binzhou Medical University Hospital, Shandong Binzhou 256603, China
  • Received:2023-01-03 Revised:2023-03-21 Online:2023-04-28 Published:2023-04-28

摘要: 司美格鲁肽是一种胰高血糖素样肽-1(GLP-1)受体激动剂,在2017年12月获美国食品和药物管理局(FDA)批准作为降糖药物应用,2021年8月正式在我国上市,自上市起一直用作降糖药物使用。由于司美格鲁肽在临床中其具有降低体重的作用,2021年6月美国FDA批准该药用于肥胖(BMI≥30 kg/m2)或超重(BMI≥27 kg/m2)成人的慢性体重管理用药。本文将从司美格鲁肽作用机制、疗效、安全性和成本分析方面概述司美格鲁肽用于超重人群体重管理的研究进展。

关键词: font-size:medium, ">司美格鲁肽;超重人群;慢性体重管理

Abstract: Semaglutide, a kind ofglucagon-like peptide-1(GLP-1)receptor agonist,It was approved by the US Food and Drug Administration(FDA) as a hypoglycemic drug in December 2017, and officially launched in China in August 2021. Semaglutide has been used as a glucose-lowering drug since its marketing, andit was approved by the United States FDA for chronic weight management in June 2021 due to its weight-reducing effect. This article reviews the research progress of semaglutide for chronic weight management in overweight population from the aspects of mechanism of action, efficacy, safety andanalysis of costs.

Key words: font-size:medium, ">Semaglutide; Overweight population;Chronic weight management

中图分类号: